Similarly, using neutralizing anti-Mertk antibodies developed by Bristol Myers Squibb, targeting Mertk on macrophages synergized with radiotherapy in improving host anti-tumor immunity towards lung adenocarcinoma in tumor bearing mice [208], as well as improved host anti-tumor immunity in triple negative breast cancer models [95]. Here, MERTK is linked to lung adenocarcinoma.